In my last Progenics Pharmaceuticals (PGNX) article, I laid out my reasoning for starting a pilot position prior to the Q4/2018 ER. The share price was bargain-basement levels and the company's projected revenue was attractive. I was confident in the technical entry and the approaching earnings had the potential to reveal a strong Q4 with AZEDRA and RELISTOR revenues. Unfortunately, the earnings was a big miss, but the share price was supported by a company press release about a potential claim to Endocyte's PSMA-617. The technical entry appeared to be successful and